Resources

Chronic Lymphocytic Leukemia (CLL), a type of slow-growing cancer of the blood and bone marrow, accounts for 25-30 percent of all leukemia in the Western world and is the most common type of leukemia in adults, with over 100,000 new global incidence cases and over 40,000 death cases reported globally in 2019. 

Phenome-Wide Association study (PheWAS) is a powerful tool designed to systematically screen clinical observations derived from medical records (phenotypes) for association with a variable of interest.

To assess the correlation between primary open-angle glaucoma (POAG) and the risk of developing diabetic retinopathy (DR) in patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM).

This infographic blog post is derived from the recent article by Jeffrey Brown, PhD, The Role of RWD and RWE in Shaping Global Regulatory Practices, published in the June 2024 issue of DIA Global Forum.

Join us for an insightful webinar that delves into the critical topic of diversity in clinical trials. This event explores using real-world data (RWD) to enhance trial design, promote health equity, and foster robust evidence generation.

In the ever-evolving landscape of healthcare, collaboration isn’t just beneficial; it’s essential. TriNetX is proud to partner with our network to advance healthcare through rigorous research, innovation, and a deep dedication to improving patient outcomes. Today, we are honored to recognize the University Medical Center Schleswig-Holstein (UKSH).

Enrich your data and expand your research opportunities as part of a global community advancing safer and more effective therapies for better patient care.

Many clinical trials struggle to enroll patients, hindering meaningful results and delaying the delivery of therapies to patients. Real-world data (RWD) addresses this by overcoming barriers such as overly strict enrollment criteria and disconnects between research design and patients’ lived experiences.

This is a retrospective cohort analysis of approximately two million people with type 2 diabetes receiving insulin across 97 healthcare organisations using a global federated health research network (TriNetX, Cambridge, USA).

Some of the most prominent and visible roles of real-world data (RWD) and real-world evidence (RWE) are regulatory and clinical decision-making and disease research. However, RWD and RWE have been growing in influence in many other areas of healthcare and in regions all over the world.

Earlier this year, the FDA rejected an application for a new cancer drug because it was based on a trial conducted in China, and the agency ruled it did not represent the U.S. population.

Concerns over reports of suicidal ideation associated with semaglutide treatment, a glucagon-like peptide 1 receptor (GLP1R) agonist medication for type 2 diabetes (T2DM) and obesity, has led to investigations by European regulatory agencies.